Future therapeutic targets in rheumatoid arthritis?

Cheung, T. T. and McInnes, I. B. (2017) Future therapeutic targets in rheumatoid arthritis? Seminars in Immunopathology, 39(4), pp. 487-500. (doi:10.1007/s00281-017-0623-3) (PMID:28451787)

[img]
Preview
Text
140803.pdf - Published Version
Available under License Creative Commons Attribution.

568kB

Abstract

Rheumatoid arthritis (RA) is a chronic inflammatory disease characterized by persistent joint inflammation. Without adequate treatment, patients with RA will develop joint deformity and progressive functional impairment. With the implementation of treat-to-target strategies and availability of biologic therapies, the outcomes for patients with RA have significantly improved. However, the unmet need in the treatment of RA remains high as some patients do not respond sufficiently to the currently available agents, remission is not always achieved and refractory disease is not uncommon. With better understanding of the pathophysiology of RA, new therapeutic approaches are emerging. Apart from more selective Janus kinase inhibition, there is a great interest in the granulocyte macrophage-colony stimulating factor pathway, Bruton's tyrosine kinase pathway, phosphoinositide-3-kinase pathway, neural stimulation and dendritic cell-based therapeutics. In this review, we will discuss the therapeutic potential of these novel approaches.

Item Type:Articles
Keywords:BTK, GM-CSF, JAK, PI3K, rheumatoid arthritis, tolerogenic dendritic cells.
Status:Published
Refereed:Yes
Glasgow Author(s) Enlighten ID:McInnes, Professor Iain
Authors: Cheung, T. T., and McInnes, I. B.
College/School:College of Medical Veterinary and Life Sciences > Institute of Infection Immunity and Inflammation
Journal Name:Seminars in Immunopathology
Publisher:Springer
ISSN:1863-2297
ISSN (Online):1863-2300
Published Online:27 April 2017
Copyright Holders:Copyright © 2017 The Authors
First Published:First published in Seminars in Immunopathology 39(4):487-500
Publisher Policy:Reproduced under a Creative Commons License

University Staff: Request a correction | Enlighten Editors: Update this record